Clinical Trial: NCT05586841
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Beijing 302 Hospital |
| Information Provided By: | Beijing 302 Hospital |
| Last Update Posted: | 2026-05-29 |
Study Overview
Brief Summary
A phase 1B study to explore the maximum tolerated dose (MTD) of dalpiciclib + chidamide in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy
Official Title
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Conditions
HR+/HER2- Advanced Breast Cancer
Intervention / Treatment
- Drug: Dalpiciclib
- Drug: Chidamide
Other Study ID Numbers
- MA-BC-II-047
Start Date (Actual)
2022-10-01
Primary Completion Date (Actual)
2025-12-30
Study Completion Date (Actual)
2026-03-30
Enrollment (Actual)
22
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Beijing 302 Hospital |
| Information Provided By: | Beijing 302 Hospital |
| Last Update Posted: | 2026-05-29 |
Study Overview
Brief Summary
A phase 1B study to explore the maximum tolerated dose (MTD) of dalpiciclib + chidamide in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy
Official Title
Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study
Conditions
HR+/HER2- Advanced Breast Cancer
Intervention / Treatment
- Drug: Dalpiciclib
- Drug: Chidamide
Other Study ID Numbers
- MA-BC-II-047
Start Date (Actual)
2022-10-01
Primary Completion Date (Actual)
2025-12-30
Study Completion Date (Actual)
2026-03-30
Enrollment (Actual)
22
Study Type
Interventional
Phase
Phase 1